Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection.

IF 1.3 4区医学 Q4 INFECTIOUS DISEASES

Antiviral Therapy Pub Date : 2024-02-01 DOI:10.1177/13596535221097495

Inès Boussen, Maud Salmona, Flore Sicre De Fontbrune, Aliénor Xhaard, Nathalie De Castro, Constance Delaugerre, Marie-Laure Chaix, Jean-Michel Molina

引用次数: 0

Abstract

We report the case of an allogeneic stem cell transplant recipient with nosocomial acquisition of SARS-CoV-2 infection who received antispike neutralizing monoclonal antibody bamlanivimab 2 days after diagnosis of SARS-CoV-2 infection but progressed to severe COVID-19 pneumonia and died with the selection of E484K/Q resistance mutations to bamlanivimab.

查看原文本刊更多论文

在一名感染 SARS-CoV-2 的同种异体干细胞移植受者中，选择 E484K 突变的巴马伊单抗治疗失败。

我们报告了一例异体干细胞移植受者的病例，该受者在确诊感染 SARS-CoV-2 2 天后接受了抗梭形病毒中和单克隆抗体巴马替尼，但病情恶化为严重的 COVID-19 肺炎，并因对巴马替尼产生 E484K/Q 抗性突变而死亡。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antiviral Therapy 医学-病毒学

CiteScore

2.60

自引率

8.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Antiviral Therapy (an official publication of the International Society of Antiviral Research) is an international, peer-reviewed journal devoted to publishing articles on the clinical development and use of antiviral agents and vaccines, and the treatment of all viral diseases. Antiviral Therapy is one of the leading journals in virology and infectious diseases. The journal is comprehensive, and publishes articles concerning all clinical aspects of antiviral therapy. It features editorials, original research papers, specially commissioned review articles, letters and book reviews. The journal is aimed at physicians and specialists interested in clinical and basic research.